Darolutamide Slows Metastasis in Prostate Cancer.
The phase III ARAMIS study shows that the androgen-receptor antagonist darolutamide delays metastasis in men with castration-resistant prostate cancer by a median of 22 months compared with a placebo. Researchers also found that side effects associated with other drugs in this class were no more common in the placebo group than the darolutamide group.